These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2939947)

  • 21. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
    Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
    Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice.
    Nahas F; Ophir R; Ben-Efraim S
    Immunol Lett; 1985; 10(6):333-7. PubMed ID: 4044020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
    Bocian RC; Ben-Efraim S; Dray S; Mokyr MB
    Cancer Immunol Immunother; 1984; 18(1):41-8. PubMed ID: 6435857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
    Rubin M; Mokyr MB
    Cancer Immunol Immunother; 1993; 36(1):37-44. PubMed ID: 8422666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
    Sojka DK; La Motte RN; Mokyr MB
    Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
    Gorelik L; Mokyr MB
    Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
    Bocian RC; Dray S; Ben-Efraim S; Mokyr MB
    Cancer Immunol Immunother; 1985; 20(1):61-8. PubMed ID: 3933817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.
    Jovasevic VM; Mokyr MB
    J Immunol; 2001 Nov; 167(9):4895-901. PubMed ID: 11673494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
    Wise JA; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
    Berko R; Seissman K; Colvin M; Bocian RC; Ben-Efraim S; Dray S
    Int J Immunopharmacol; 1988; 10(7):825-34. PubMed ID: 3235239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
    Sojka DK; Donepudi M; Bluestone JA; Mokyr MB
    J Immunol; 2000 Jun; 164(12):6230-6. PubMed ID: 10843675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. THF-gamma 2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma.
    Ophir R; Pecht M; Halperin D; Rashid G; Burstein Y; Ben-Efraim S; Trainin N
    Cancer Immunol Immunother; 1989; 30(2):119-25. PubMed ID: 2598178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.
    Ben-Efraim S; Bocian RC; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1983; 15(2):101-7. PubMed ID: 6553510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.
    Schwarzbard Z; Ophir R; Gotlieb-Stematsky T; Benefraim S
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1069-75. PubMed ID: 2998801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
    Ophir R; Pecht M; Burstein Y; Harshemesh H; Ben-Efraim S; Trainin N
    Int J Cancer; 1991 Apr; 48(1):96-100. PubMed ID: 2019463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.
    Shoval S; Ophir R; Ben-Efraim S
    Cancer Immunol Immunother; 1989; 29(4):279-87. PubMed ID: 2787695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.